伊赛珠单抗治疗后男性生育力得以保留——一项真实世界初步研究
这项前瞻性初步研究连续纳入10例适合或正在接受伊赛珠单抗(IXE)治疗的成年男性脊柱关节炎(SpA)和/或银屑病(PsO)患者,在至少6个月IXE治疗后进行精液分析,部分患者治疗前也检测,并与健康供精者对照。结果显示所有患者精液参数正常,1例基线少精症患者随访恢复正常并成功妊娠;与对照相比,IXE治疗患者精子浓度较低但活力较高。作者认为IXE暴露未损害男性生育力。
要点
- 10例SpA和/或PsO男性患者接受IXE至少6个月后精液参数均正常。
- 1例基线少精症的SpA合并PsO患者治疗后精液参数正常并成功妊娠。
- 与健康对照相比,IXE治疗患者精子浓度较低但活力较高。
核心结论
- 在这项样本量有限的SpA和PsO患者初步研究中,IXE暴露未损害男性生育力。
- 至少6个月治疗后精液参数保持在正常范围内。
- 早期IXE治疗可能保留或潜在逆转生育力损害。
研究设计与样本
- 前瞻性初步研究,连续纳入适合或正在接受IXE治疗的成年男性SpA和/或PsO患者。
- 记录人口学数据、疾病特征、实验室评估、合并症和既往治疗。
- 在至少6个月IXE治疗后进行精液分析,部分患者治疗前也检测。
- 对照组为健康供精者,进行平行精液评估。
主要发现
- 共纳入10例患者:8例SpA和2例PsO。
- 至少6个月IXE治疗后,所有患者精液参数正常。
- 1例基线少精症的SpA合并PsO患者随访时精液参数正常,治疗后成功妊娠。
- 与对照组相比,IXE治疗患者精子浓度较低但活力较高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者称本研究为样本量有限的初步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Preserving fertility is crucial when managing male patients with spondyloarthritis (SpA) and/or psoriasis (PsO), especially in young men. Chronic inflammation, hormonal dysregulation and immunosuppressive therapies can negatively impact male fertility. Over the past decades, positive data have emerged regarding the reproductive safety of various therapies in men. Ixekizumab (IXE), a high-affinity monoclonal antibody targeting IL-17A, has shown a safe profile for male fertility in small studies. This pilot study assesses the impact of IXE treatment on sperm parameters in SpA and/or PsO patients in a real-world setting. METHODS: Consecutive adult male SpA and/or PsO patients eligible for or undergoing IXE treatment were prospectively enrolled. Demographic data, disease characteristics, laboratory assessments, comorbidities and previous treatments were recorded. Sperm analysis was conducted after a minimum of 6 months of IXE treatment, and also before treatment inititation in a subgroup of patients. Parallel sperm evaluations were performed in a control group of healthy donors. RESULTS: Ten patients were enrolled: eight with SpA and two with PsO. After 6 months of IXE treatment, all patients had normal sperm parameters. One SpA and PsO patient with baseline oligozoospermia showed normal parameters at follow-up and achieved a successful pregnancy post-treatment. Compared with controls, IXE-treated patients had lower sperm concentrations but higher vitality. CONCLUSION: In our limited-size pilot study on SpA and PsO patients, IXE exposure did not impair male fertility. Sperm parameters remained within normal ranges after a minimum of 6 months of treatment. Early IXE treatment may preserve or potentially reverse fertility impairment.
引用
- Micu MC, Farina N, Decean HP, et al. Male fertility is preserved following ixekizumab treatment-a real-life pilot study. Rheumatology (Oxford). 2025. PMID: 39499188. doi:10.1093/rheumatology/keae609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。